Brown Rudnick Advises World-Leading COVID Rapid Test Provider Excalibur Healthcare on Groundbreaking Licence and Development Agreement with Sensyne Health
PUBLISHED ON: 02/17/2021
LONDON - 17 February 2021 – International law firm Brown Rudnick advised leading rapid COVID-19 diagnostic test provider Excalibur Healthcare Services on an exclusive licence and development agreement with AIM-listed Sensyne Health for the use of Excalibur’s tests in conjunction with Sensyne Health’s clinical AI software, ‘MagnifEye.’ The aim of the collaboration is to deliver the most accurate rapid lateral flow COVID-19 test in the world.
The initial focus of the collaboration will be for the use of the ‘MagnifEye’ technology for COVID-19 antigen testing, followed by its potential application in new lateral flow diagnostic tests for serology, cancer, and other disease conditions that Excalibur is currently developing.
Excalibur’s rapid SARS COV-2 antigen screening test was the first ever lateral flow antigen test to receive UK regulatory approval for use in mass screening for COVID-19 in asymptomatic, presymptomatic, and symptomatic populations. To date, the Excalibur COVID-19 antigen lateral flow diagnostic test has outperformed all other competing lateral flow tests with its speed, sensitivity, and reliability.
The partner-led team at Brown Rudnick was selected by UK-headquartered Excalibur for its collaborative approach and for the Firm’s transatlantic advisory and transaction capabilities across life sciences and IP. It is anticipated that the collaboration between Excalibur and Sensyne Health will deliver time-sensitive and cutting-edge solutions that will have a major impact in the global fight against COVID-19.
Professor Sir Chris Evans, chairman and CEO, Excalibur Healthcare Services said: “Our partnership with Sensyne Health plc, a leading UK-based clinical AI company marks another positive development for UK science and technology. Scientific efforts to combat COVID-19 are happening at unprecedented speed and we needed a legal team with strong competences across IP, life sciences, and healthcare technology able to work with a great sense of urgency.
We are very grateful to the highly experienced team at Brown Rudnick who succeeded on all accounts. They combined impressive sector knowledge and flawless execution to help us get this deal done at speed, so that our team can focus on the urgent task of developing tests that detect even lower viral loads of SARS-COV-2 and help to stem the spread of this pandemic.”
Steven James and Neil Micklethwaite, partners at Brown Rudnick said: “It has been a real honour to work with two market leading companies whose ambition, purpose and efforts are jointly dedicated to help solve the most urgent health and diagnostic challenges of our lifetime, with the potential to improve lives all over the world.”
The Brown Rudnick team includes Neil Micklethwaite, managing partner of Brown Rudnick’s London office, Steven James, partner in the Intellectual Property Practice Group and Ruth Arkley, associate.
About Brown Rudnick LLP
Brown Rudnick combines ingenuity with experience to achieve great outcomes for our clients. We deliver partner-driven services, incentivize our lawyers to collaborate in the client’s best interest, and put excellence before scale. We focus on practices such as distressed debt, corporate restructuring, litigation, M&A, white collar defense, international disputes and intellectual property, where we are a recognized leader. We have more than 250 lawyers and government relations professionals across the United States and Europe, with offices in key financial centers. Beyond the United States and Europe, we serve clients in the Middle East, North Africa, the Caribbean, and Latin America.